OSI Pharmaceuticals have initiated a Phase I trial of its dual serotonin and norepinephrine reuptake inhibitor/5-HT1A agonist which is under development for the treatment of obesity.
Filed under: gpcr | Tagged: 5-HT1A, 5HT1A, agonist, OSI, phase I, PSN-602, PSN602
